Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing.

William E. Dager, Judith C. Andersen, Edith Nutescu
Published 2004 in Pharmacotherapy

Abstract

Multiple options for anticoagulation therapy are now available, placing an additional responsibility on health care workers for choosing the optimal therapy for each patient. The heparins carry a risk of heparin-induced thrombocytopenia (HIT), an immune-mediated reaction to heparin that may lead to pulmonary embolism and death. Fondaparinux, a new… (More)

Topics

1 Figure or Table

figure 1

Cited By

[Use of fondaparinux during hemodialysis in heparin-induced thrombocytopenia. About a new observation].

Richard Montagnac, Saïd Brahimi, Pascale Janian, Jean-Pierre Melin, Jean-Philippe Bertocchio, Alain Wynckel
Nephrologie & therapeutique
2010

Venous thromboembolism prophylaxis and wound healing in patients undergoing major orthopedic surgery.

Barry J Snyder, Barry J Waldman
Advances in skin & wound care
2009

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes

Alex C Spyropoulos, Sharyl Magnuson, Sei Keng Koh
Therapeutics and clinical risk management
2008

Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction.

Matthias Nahrendorf, Elena Aikawa, +7 authors Ralph Weissleder
European heart journal
2008

The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options.

Giancarlo Agnelli, Joseph A Caprini
Journal of surgical oncology
2007

Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation.

Skevos K Sideris, Michael J Bonios, +4 authors John S Kogias
Hellenic journal of cardiology : HJC = Hellenike…
2005

References

Sort by:

Showing 1-10 of 40 references

U. S. Foo
Application 21–345 medical review. Available from…
2004

Advancements in minimally invasive total hip arthroplasty.

Barry J Waldman
Orthopedics
2003

Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.

Bengt I Eriksson, Michael R Lassen
Archives of internal medicine
2003

EC Lian, L Chua, E. Oberstein
Blood
2003

Pharmacotherapy of heparin- induced thrombocytopenia.

William E Dager, Richard H White
Expert opinion on pharmacotherapy
2003

Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

H R Büller, B L Davidson, +9 authors A W A Lensing
The New England journal of medicine
2003

Kuo KHM, Kovacs MJ
Blood
2003

J Sanchez-Ballaster, MG Smith, S Kershaw
Presented at the annual meeting of the American…
2003

Delayed-onset heparin-induced thrombocytopenia.

Lawrence Rice, Walid K Attisha, Alane Drexler, John L Francis
Annals of internal medicine
2002

Heparin-induced thrombocytopenia.

Theodore E Warkentin
Disease-a-month : DM
2002

Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing.

Abstract

Topics

1 Figure or Table

Cited By

[Use of fondaparinux during hemodialysis in heparin-induced thrombocytopenia. About a new observation].

Venous thromboembolism prophylaxis and wound healing in patients undergoing major orthopedic surgery.

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes

Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction.

The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options.

Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation.

References

and Drug Administration, Center for Drug Evaluation and Research

Advancements in minimally invasive total hip arthroplasty.

Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.

Long-term use of fondaparinux in a patient with antiphospholipid syndrome, heparin-induced thrombocytopenia and refractoriness to coumarin [abstr

Pharmacotherapy of heparin- induced thrombocytopenia.

Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux [abstr

Wound infection in the management of hip fractures: a comparison between subcutaneous low-molecular weight heparin and no thromboprophylaxis

Delayed-onset heparin-induced thrombocytopenia.

Heparin-induced thrombocytopenia.

Slides referencing similar topics

Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing.

Abstract

Topics

1 Figure or Table

Cited By

[Use of fondaparinux during hemodialysis in heparin-induced thrombocytopenia. About a new observation].

Venous thromboembolism prophylaxis and wound healing in patients undergoing major orthopedic surgery.

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes

Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction.

The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options.

Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation.

References

and Drug Administration, Center for Drug Evaluation and Research

Advancements in minimally invasive total hip arthroplasty.

Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.

Long-term use of fondaparinux in a patient with antiphospholipid syndrome, heparin-induced thrombocytopenia and refractoriness to coumarin [abstr

Pharmacotherapy of heparin- induced thrombocytopenia.

Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux [abstr

Wound infection in the management of hip fractures: a comparison between subcutaneous low-molecular weight heparin and no thromboprophylaxis

Delayed-onset heparin-induced thrombocytopenia.

Heparin-induced thrombocytopenia.

Similar Papers

Slides referencing similar topics